• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 5, 2016

View Archived Issues

Symphogen gets $175M up front in a $1.775B Baxalta immuno-oncology alliance

DUBLIN – Symphogen A/S and Baxalta Inc. jointly made a major statement of intent in immuno-oncology, with an alliance focused on up to six immune checkpoint targets, under which Symphogen is getting $175 million up front plus up to $1.6 billion more in option fees and milestone payments. Read More

Big VC financing rounds lead to monster 4Q

Venture capitalists hit the ground running after returning from their summer vacations that saw third-quarter investments fall substantially from the first half. (See BioWorld Today, Oct. 2, 2015.) Read More

H1N1 swine flu shows the potential to transmit in humans

HONG KONG – Chinese virologists have discovered that following a lengthy evolutionary period in pigs, Eurasian H1N1 avian-like (EAH1N1) swine influenza viruses (SIVs) have acquired the ability to transmit effectively in humans, suggesting that urgent action may be necessary in order to prevent a new readily transmissible swine flu epidemic. Read More

Scholar 'Rock on' $36M series B shows faith in growth factor activation

Scholar Rock Inc., the 2-year-old company pursuing drugs that target supracellular activation of growth factors, jump-started its New Year with a $36 million series B financing. Read More

Teva, Active stop high dose of MS drug after heart troubles surface

Teva Pharmaceutical Industries Ltd. and Active Biotech AB said that testing of 1.2 mg and 1.5 mg doses of the experimental multiple sclerosis (MS) therapy laquinimod have been discontinued in two ongoing studies of the drug after eight patients experienced non-fatal cardiovascular (CV) events. Read More

India revises essential medicines list and adds 106 new drugs

NEW DELHI – In another of several dramatic twists and turns over the past two years, India ended 2015 with a revision to its National List of Essential Medicines (NLEM), including some new drugs and knocking others off to raise the total number of medicines to 376. Read More

Pandorum's printed liver tissue will help with drug development

NEW DELHI – Bangalore-based biotechnology start-up Pandorum Technologies Pvt Ltd. has developed artificial 3-D liver tissue that can mimic a human liver and be used in lieu of living tissue for human trials. The company said its artificial tissues and mini-organs are suitable for high-throughput drug and vaccine discovery, mechanistic toxicology and medical research, and that its ultimate vision is "on-demand manufacturing of human organs." Read More

BioWorld adjusts reporting, data analysis parameters

Innovation in drug development has spread well beyond the confines of traditional biotechnology companies. As such, starting in 2016, we are making several important changes in the way we analyze the business and financial developments of the industry in BioWorld Today, BioWorld Insight and BioWorld Snapshots. Read More

Regulatory front

Circling back around to a draft guidance first proposed more than eight years ago, the FDA is once again seeking comment for Office of Management and Budget (OMB) approval of an information collection on the draft, "Target product profile – a strategic development process tool." Read More

Financings

Halozyme Therapeutics Inc., of San Diego, said it has entered a $150 million credit agreement, secured by future royalties of Enhanze products, received only from the company's collaborations with Roche AG, of Basel, Switzerland, and Baxalta Inc., of Bannockburn, Ill. The financing will be facilitated through investment funds managed by Pharmakon Advisors and Athyrium Capital Management. Read More

Other news to note

Anticancer Inc., of San Diego, said it has a new approach to hair transplantation developed using frozen cryopreserved hair follicles. Healthy mouse hair follicles were cryopreserved at -80 degrees C and upon thawing and transplantation to hairless nude mice, the transplanted follicles produced extensive hair growth similar to fresh follicles. Read More

In the clinic

Xenikos BV, of Nijmegen, the Netherlands, said researchers in the Netherlands and Germany have reported positive interim results of a phase I/II study with T-Guard for treatment of steroid-resistant, acute, graft vs. host disease. T-Guard is a combination of two toxin-loaded anti-T-cell antibodies that shows promise as a therapeutic tool for safely and swiftly resetting the body's immune system in T-cell mediated diseases, the company said. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe